About Cystic Fibrosis 

Cystic Fibrosis (CF) is the most common life-threatening recessive genetic condition affecting Australian children today.  Every four days a baby is born with CF and there are nearly a million Australians who are genetic carriers of the disease.  

CF primarily affects the lungs and digestive system.  The CF gene causes normal mucus to change into a thick, sticky substance, clogging the tiny air passages in the the lungs and trapping bacteria.  Repeated infections and blockages cause irreversible lung damage and, ultimately death.  People who have CF must have daily intensive chest therapy to combat the build up of mucus in the lungs.  Most must also take digestive enzyme replacement tablets with food and drink to aid digestion.  This can mean taking up to 40 tablets per day.

For more information visit http://www.cysticfibrosis.org.au/


Cystic Fibrosis Australia

Cystic Fibrosis Australia (CFA) is the national body for cystic fibrosis (CF) and works with State and Territory partners to achieve national priorities, including: ensuring the availability and accessibility of new treatments, funding vital research, advocating for increased support and quality improvement in health care to people with CF, and generally providing direct benefits to every person living with CF in Australia.

CFA is comitted to impriving clinical practice and patient outcomes through its Quality Improvement Programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.  

This will be achieved through:

Advocacy

Cystic Fibrosis Australia (CFA) has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media. CFA also supports state and territory CF bodies who provide valuable services to the CF community.

CFA works tirelessly to raise the profile of Cystic Fibrosis nationally and takes key messages to government, business and the health and community sectors to ensure these groups to understand and appreciate the challenges people with CF face. These include key issues such as drug affordability and availability, infection control, gene testing and access to the best medical and allied health services.

Funding

CFA is responsible for creating innovative and enduring funding streams, cost and service effective business practices and a positive culture of support, respect and celebration.

We will maintain our quest for funding to ensure our research and clinical improvement assets such as the Data Registry, Peer Reviews and Standards of Care continue to thrive and to fulfil our mission to deliver research and information as the peak national body supporting state and territory members with their goals to enhance the quality of life of people affected by CF.

Collaboration

Cystic Fibrosis Australia encourages collaboration to ensure the best gains are achieved in the fasted time, knowledge is shared, breakthroughs are celebrated and funds are not wasted through duplication.

CFA collaborates with government entities, health service providers, research groups, NFPs in the health and chronic disease sectors and overseas colleagues and foundations.

Collaboration will allow us to be smarter with our research, services and clinical improvement programs but most importantly it will deliver better outcomes more quickly for people with Cystic Fibrosis.

For more information, contact the Cystic Fibrosis Austalia office on (02) 9889 5171 or via our website. 


powered by Everyday Hero